Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

Phase I, Double-blind, Randomized, Placebo-controlled, Single-center Study to Assess the Safety and Tolerability of RNS60 Administered Intravenously to Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01264783

Enrollment

Registered

2010-12-22

Start date

2011-07-31

Completion date

2011-09-30

Last updated

2011-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarct

Brief summary

The objective of this study is to evaluate the safety and tolerability of RNS60 administered intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three escalating rates for 48 hours for each rate.

Interventions

DRUGRNS60

RNS60 for intravenous administration

DRUGPlacebo

0.9% normal saline for injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Males between 18-55 years * Minimum body weight of 60 kg * BMI of 18-32 kg/m2 * Able to execute informed written consent

Exclusion criteria

* A chronic or acute disease that might interfere with the evaluation of the safety of RNS60 * Current or prior malignancies (excluding history of treated non-melanoma skin carcinoma) * Positive viral serology test for HBsAG, Hep C antibody, Hep A IgM, or HIV * Use of any prescription medications within 2 weeks of the first day of dosing * Significant organ dysfunction, including cardiac, renal, liver, CNS, pulmonary, vascular, GI, endocrine or metabolic * Treatment with monoclonal antibody therapy within 5 half-lives prior to the first dose of study medication * Treatment with any investigational drugs or therapies within 30 days (or 5 half-lives, whichever is greater) prior to the first dose of study medication * Abnormal pre-admission vital signs, physical exam, clinical laboratory, or any safety variable considered clinically significant for this population by the PI * Subject is considering or has scheduled any surgical procedure during participation in study * History of alcohol and/or dug abuse within 1 year prior to first dose of study medication * Subject has donated plasma or blood within 30 days prior to first dose of study medication * Subject requires treatment with any medications, either prescription or nonprescription, including dietary supplements or herbal medications, within 14 days prior to the first dose of study medication. Exceptions are nonprescription topical medications (that are not systemically absorbed), acetaminophen, or vitamins at recommended daily doses (not mega dose vitamins) * A positive qualitative urine drug or alcohol test * Concurrent enrollment in any other clinical trial * Subject is judged by PI or Medical Monitor to be inappropriate for the study - * Subject has Gilbert's syndrome * Subject has estimated creatinine clearance at screening of \<90 mL/min.

Design outcomes

Primary

Measure	Time frame	Description
Tolerability	6 days	Safety and tolerability of RNS60 administered by IV infusion to healthy volunteers.

Secondary

Measure	Time frame	Description
Biomarkers	6 days	Analysis of blood samples for various biomarkers

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026